港股异动 | 华领医药-B(02552)涨超3% 第二代GKA美国MAD Ib期试验成功给药 未来拟寻求合作伙伴

Core Viewpoint - HuaLing Pharmaceutical-B (02552) has seen a stock increase of over 3% following the successful administration of the first patient in the MAD Ib trial of its second-generation glucose kinase activator (GKA), HMS1005, in the United States [1][2] Group 1: Trial Details - The MAD Ib trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMS1005 in Type 2 diabetes (T2D) patients in the U.S. [1] - The study will assess pharmacodynamic markers such as blood glucose, insulin, C-peptide, GLP-1, and glucagon, as well as monitor blood glucose fluctuations using continuous glucose monitoring (CGM) [1] Group 2: Drug Characteristics - HMS1005 is a new molecular entity with improved physicochemical properties, designed as a sustained-release formulation to allow once-daily dosing, enhancing patient convenience and increasing the duration of the drug's action in the intestine [2] - The company has previously completed and published results from a single-dose escalation study of HMS1005, confirming its feasibility for once-daily oral treatment in T2D and obesity patients [2] Group 3: Future Plans - Following the successful completion of the MAD Ib trial, the company plans to seek partners for the global development of HMS1005 [2]

HUA MEDICINE-港股异动 | 华领医药-B(02552)涨超3% 第二代GKA美国MAD Ib期试验成功给药 未来拟寻求合作伙伴 - Reportify